Active, not recruitingPhase 1NCT04629729

FT819 in Subjects With B-cell Malignancies

Studying T-cell prolymphocytic leukemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fate Therapeutics
Principal Investigator: Fate Trial Disclosure
Fate Therapeutics
Intervention: FT819(drug)
Enrollment: 54 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2039

Study locations (18)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Arizona, Phoenix, Arizona, United States
UC Davis, Davis, California, United States
Scripps Green Hospital, La Jolla, California, United States
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
University of Florida, Gainesville, Florida, United States
Mayo Florida, Jacksonville, Florida, United States
University of Iowa, Iowa City, Iowa, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
Mayo Minnesota, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
+3 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04629729 on ClinicalTrials.gov

Other trials for T-cell prolymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for T-cell prolymphocytic leukemia →

← Back to all trials